These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37088121)

  • 1. MLX plays a key role in lipid and glucose metabolism in humans: Evidence from in vitro and in vivo studies.
    Nagarajan SR; Livingstone EJ; Monfeuga T; Lewis LC; Ali SHL; Chandran A; Dearlove DJ; Neville MJ; Chen L; Maroteau C; Ruby MA; Hodson L
    Metabolism; 2023 Jul; 144():155563. PubMed ID: 37088121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
    Smith GI; Shankaran M; Yoshino M; Schweitzer GG; Chondronikola M; Beals JW; Okunade AL; Patterson BW; Nyangau E; Field T; Sirlin CB; Talukdar S; Hellerstein MK; Klein S
    J Clin Invest; 2020 Mar; 130(3):1453-1460. PubMed ID: 31805015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic glucokinase regulatory protein and carbohydrate response element binding protein attenuation reduce de novo lipogenesis but do not mitigate intrahepatic triglyceride accumulation in Aldob deficiency.
    Buziau AM; Oosterveer MH; Wouters K; Bos T; Tolan DR; Agius L; Ford BE; Cassiman D; Stehouwer CDA; Schalkwijk CG; Brouwers MCGJ
    Mol Metab; 2024 Sep; 87():101984. PubMed ID: 38972375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver.
    Hörbelt T; Knebel B; Fahlbusch P; Barbosa D; de Wiza DH; Van de Velde F; Van Nieuwenhove Y; Lapauw B; Thoresen GH; Al-Hasani H; Müller-Wieland D; Ouwens DM; Kotzka J
    Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2671-2684. PubMed ID: 31336149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mlx is the functional heteromeric partner of the carbohydrate response element-binding protein in glucose regulation of lipogenic enzyme genes.
    Stoeckman AK; Ma L; Towle HC
    J Biol Chem; 2004 Apr; 279(15):15662-9. PubMed ID: 14742444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis.
    Green CJ; Marjot T; Walsby-Tickle J; Charlton C; Cornfield T; Westcott F; Pinnick KE; Moolla A; Hazlehurst JM; McCullagh J; Tomlinson JW; Hodson L
    Eur J Endocrinol; 2022 Feb; 186(3):367-377. PubMed ID: 35038311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct role of ChREBP.Mlx in regulating hepatic glucose-responsive genes.
    Ma L; Tsatsos NG; Towle HC
    J Biol Chem; 2005 Mar; 280(12):12019-27. PubMed ID: 15664996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct and systemic actions of growth hormone receptor (GHR)-signaling on hepatic glycolysis, de novo lipogenesis and insulin sensitivity, associated with steatosis.
    Vázquez-Borrego MC; Del Río-Moreno M; Pyatkov M; Sarmento-Cabral A; Mahmood M; Pelke N; Wnek M; Cordoba-Chacon J; Waxman DJ; Puchowicz MA; McGuinness OP; Kineman RD
    Metabolism; 2023 Jul; 144():155589. PubMed ID: 37182789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
    Liu X; Chen S; Zhang L
    Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
    Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH
    Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
    Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
    Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.
    Benhamed F; Denechaud PD; Lemoine M; Robichon C; Moldes M; Bertrand-Michel J; Ratziu V; Serfaty L; Housset C; Capeau J; Girard J; Guillou H; Postic C
    J Clin Invest; 2012 Jun; 122(6):2176-94. PubMed ID: 22546860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Transcription factor ChREBP – the coordinator of carbohydrate and lipid metabolism].
    Krawczak J; Owczarek A; Winiarska K
    Postepy Biochem; 2020 Mar; 66(1):30-37. PubMed ID: 33320482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Noncoding RNA lncSHGL Recruits hnRNPA1 to Suppress Hepatic Gluconeogenesis and Lipogenesis.
    Wang J; Yang W; Chen Z; Chen J; Meng Y; Feng B; Sun L; Dou L; Li J; Cui Q; Yang J
    Diabetes; 2018 Apr; 67(4):581-593. PubMed ID: 29382663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-carbohydrate diets induce hepatic insulin resistance to protect the liver from substrate overload.
    Agius L
    Biochem Pharmacol; 2013 Feb; 85(3):306-12. PubMed ID: 23022226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis.
    Buyl K; Vrints M; Fernando R; Desmae T; Van Eeckhoutte T; Jans M; Van Der Schueren J; Boeckmans J; Rodrigues RM; De Boe V; Rogiers V; De Kock J; Beirinckx F; Vanhaecke T
    Eur J Pharmacol; 2023 Oct; 957():175989. PubMed ID: 37572939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
    Geisler CE; Renquist BJ
    J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity.
    Zhang S; Guo F; Yu M; Yang X; Yao Z; Li Q; Wei Z; Feng K; Zeng P; Zhao D; Li X; Zhu Y; Miao QR; Iwakiri Y; Chen Y; Han J; Duan Y
    J Hepatol; 2020 Dec; 73(6):1482-1495. PubMed ID: 32738448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars.
    Luukkonen PK; Sädevirta S; Zhou Y; Kayser B; Ali A; Ahonen L; Lallukka S; Pelloux V; Gaggini M; Jian C; Hakkarainen A; Lundbom N; Gylling H; Salonen A; Orešič M; Hyötyläinen T; Orho-Melander M; Rissanen A; Gastaldelli A; Clément K; Hodson L; Yki-Järvinen H
    Diabetes Care; 2018 Aug; 41(8):1732-1739. PubMed ID: 29844096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.